(NTLA) Intellia Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NTLA) Intellia Therapeutics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Intellia Therapeutics, Inc. BCG Matrix helps you quickly understand how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
No true Stars yet
Intellia had no approved product revenue by end-2025, so it had no true Star in the classic BCG sense. Its closest Star-like assets were late-stage CRISPR programs, led by nexiguran ziclumeran and lonvoguran ziclumeran, which target large addressable markets but were still pre-commercial. In 2025, revenue was still only collaboration-based, not product sales.
NTLA-2001, ATTR amyloidosis
NTLA-2001 is Intellia Therapeutics, Inc.'s lead in vivo CRISPR asset, and it has shown deep, one-dose serum TTR knockdown of about 90%+ in early studies. ATTR amyloidosis is a growing rare-disease market, with an estimated tens of thousands affected in the United States and clear unmet need. If safety, efficacy, and FDA execution hold, this is Intellia Therapeutics, Inc.'s clearest future Star.
NTLA-2002, hereditary angioedema
NTLA-2002 is a late-stage in vivo gene-editing asset for hereditary angioedema, a rare disease affecting about 1 in 50,000 people. HAE is a small market, but it has high value because patients often need lifelong prophylactic therapy, so recurring demand is strong. If one-time dosing gives durable attack control, NTLA-2002 could win major share in a premium specialty niche.
In vivo liver-editing platform
Intellia Therapeutics, Inc.'s in vivo liver-editing platform is a Star because it uses one CRISPR/Cas9 liver-delivery engine across several monogenic diseases, so each new program lowers reinvention risk. NTLA-2001 showed a mean 91% serum TTR reduction at 12 months in ATTR amyloidosis, proving the platform can cut deep in humans.
One liver-delivery engine, many indications
Best proof point: 91% TTR cut at 12 months
High growth, but heavy R&D spend
Hemophilia A and B programs
Intellia Therapeutics, Inc.'s hemophilia A and B programs sit in a high-value rare-disease niche; hemophilia A affects about 1 in 5,000 male births and hemophilia B about 1 in 25,000. Regeneron co-development adds scale and outside validation, which strengthens the Stars case. If the gene-editing readouts hold, these programs could win a premium share in a multi-billion-dollar market.
- Rare disease, high pricing power
- Regeneron backs scale and credibility
- Big upside if clinical data hold
Intellia’s CRISPR Edge Hinges on Late-Stage Data
Intellia Therapeutics, Inc. has no product-sales Star yet, but its lead in vivo CRISPR assets are the closest fit. NTLA-2001 showed about 91% serum TTR reduction at 12 months in ATTR, and NTLA-2002 targets hereditary angioedema, a rare but high-value market. The Star case depends on late-stage data, FDA execution, and durable one-dose outcomes.
| Asset | Star case | Key data |
|---|---|---|
| NTLA-2001 | Strongest | 91% TTR cut |
| NTLA-2002 | High upside | HAE target |
What is included in the product
Detailed Word Document
Intellia’s BCG Matrix maps its gene-editing pipeline to spot stars, question marks, cash drains, and divest candidates.
Editable Excel File
One-page Intellia Therapeutics BCG Matrix that clarifies portfolio priorities and reduces strategic guesswork
Reference Sources
Provides a traceable source trail for Intellia Therapeutics, Inc., helping validate key claims and support faster, more confident decisions.
Cash Cows
No true Cash Cows yet
Intellia Therapeutics had no marketed product by end-2025, so it had no true Cash Cow or steady product-sales engine. Product revenue was still $0, and the company kept funding R&D with cash, collaboration income, and capital-market financing instead of mature operating cash flow. That fits a high-burn biotech profile, not a classic low-growth, high-share Cash Cow.
Regeneron collaboration
The Regeneron collaboration is Intellia Therapeutics, Inc.'s key cash-supportive channel, with economics from research funding, milestones, and shared program value. It helps fund hemophilia work, but it is not a steady product annuity like a mature drug franchise. Intellia ended 2024 with $1.2 billion in cash, cash equivalents, and marketable securities, so this deal matters, but it is still a support engine, not the core cash cow.
Novartis collaboration
Novartis remains a partner-backed value source for Intellia Therapeutics, Inc., supporting hematopoietic stem cell engineering work for sickle cell disease. This is still option value, not a true cash cow from sales: Intellia reported no product revenue from this tie-up, only collaboration support and milestone-style funding in its 2025 filings.
SparingVision alliance
The SparingVision alliance broadens Intellia Therapeutics, Inc.'s reach in ocular genome medicine, but it is still more of a partnered option than a true cash cow. Intellia reported cash, cash equivalents, and marketable securities of $1.2 billion at June 30, 2025, so alliance cash helps fund R&D while limiting direct spend.
Upfront and milestone payments can support revenue, but the market share signal is still absent because the asset is early and not commercial.
- Expands ocular genome medicine reach
- Brings upfront and milestone cash
- Limits Intellia's direct spending
- Market share is still not visible
Ospedale San Raffaele collaboration
Ospedale San Raffaele collaboration adds research depth and external validation for Intellia Therapeutics, Inc., but it is not a market-leading cash engine. Intellia ended 2024 with about $1.0 billion in cash, cash equivalents, and marketable securities, so this tie-up mainly supports science and non-product funding. It is useful cash support, not a mature Cash Cow.
- External scientific validation
- Supports non-product funding
- Not a mature cash generator
Intellia Has No Cash Cow—Just Partnerships and Cash Reserves
Intellia Therapeutics, Inc. has no true Cash Cow in its BCG mix because it had no marketed product and no product revenue through 2025. Its cash support comes from alliances like Regeneron, Novartis, SparingVision, and Ospedale San Raffaele, plus $1.2 billion in cash, cash equivalents, and marketable securities at June 30, 2025. These are funding sources, not mature, low-growth profit engines.
| Cash Cow signal | Data point |
|---|---|
| Product revenue | $0 in 2025 |
| Cash, cash equivalents, marketable securities | $1.2 billion at June 30, 2025 |
| Status | No marketed product |
Get Your Copy
Intellia Therapeutics, Inc. Reference Sources
You’re previewing the exact Intellia Therapeutics, Inc. BCG Matrix report you’ll receive after purchase. The full document is the same professionally formatted file—no demo content, no hidden changes. Once purchased, it’s ready to download, review, and use for strategic analysis right away.
Dogs
No true Dogs yet
By end-2025, Intellia Therapeutics, Inc. still had no approved legacy brands, so there was no clear low-growth, low-share product to divest. Its weak spots were early-stage pipeline risk, not mature underperformers. The company reported $0 product revenue in 2025, so the Dogs bucket stayed empty.
Non-core exploratory programs
Intellia Therapeutics, Inc.’s non-core exploratory programs sit outside its lead liver franchise, so they have low visibility and long timelines. In FY2024, Intellia still had no commercial product revenue, which makes these early assets harder to justify inside BCG terms unless they show clear data and partner pull. If they stay small and unfunded, they are the closest fit to Dogs.
Early ex vivo oncology work
Intellia Therapeutics, Inc.'s early ex vivo oncology work fits Dogs: it is capital heavy, slow to de-risk, and crowded with CAR-T rivals. Ex vivo cell therapy programs often need $50M-$100M+ a year before pivotal data, so weak differentiation can drain cash fast if timelines slip.
Academic collaborations without product sales
Academic collaborations help Intellia Therapeutics, Inc. build CRISPR science, but they do not create product sales or real market share. In the latest reported period, revenue still came from collaborations and grants, not marketed drugs, so these ties stay weak as standalone BCG assets. They are best viewed as Question Marks, not Cash Cows.
- No commercial product revenue.
- Science value, weak scale.
- Revenue depends on partners.
- Low BCG strength alone.
Deprioritized platform bets
Intellia Therapeutics has 2 lead late-stage assets, NTLA-2001 and NTLA-2002, so any pipeline work not tied to them is exposed to reprioritization. These side programs can still burn R&D cash without a near-term payoff, which makes them weak BCG Dogs if they do not move forward. In a $1B-plus development budget setting, management will likely protect the highest-value shots first.
- 2 lead late-stage assets drive priority
- Non-core programs face R&D cuts
- No advance, no Dog-zone escape
Intellia’s Dogs Bucket Stays Empty With No Product Revenue
Intellia Therapeutics, Inc.’s Dogs bucket is mostly empty because there is no approved product, no product revenue in 2025, and no mature brand to harvest or divest. Any weak fit comes from small, non-core programs that burn cash without near-term scale, so they stay low-share, low-return assets.
| Dog signal | 2025/2026 data |
|---|---|
| Product revenue | $0 in 2025 |
| Approved drugs | None |
| Core priority | NTLA-2001, NTLA-2002 |
| Dog fit | Weak, non-core programs only |
Question Marks
NTLA-3001, alpha-1 antitrypsin deficiency
NTLA-3001 is a low-share Question Mark because it is still developmental, but alpha-1 antitrypsin deficiency is a real rare-disease market, affecting about 1 in 2,000 to 1 in 5,000 people of European ancestry. If Intellia Therapeutics, Inc. proves durable liver edit results, the program could move toward Star status. Until then, it needs heavy R&D spend and clinical proof.
NTLA-5001, acute myeloid leukemia
NTLA-5001 targets acute myeloid leukemia, a high-need market with about 20,000 new U.S. cases a year and poor 5-year survival near 30%. Intellia Therapeutics, Inc.’s ex vivo program is still early and has no commercial revenue, so its market share is effectively zero. That mix of big demand and low proof fits a classic Question Mark in the BCG Matrix.
Hemophilia A and B, early market capture
Hemophilia A and B remain an attractive market for Intellia Therapeutics, but the company still has no commercial share. As of 2025, its hemophilia assets are still in development, so value depends on clean clinical data, safety, and partner execution, not sales.
That keeps the segment a high-potential Question Mark: big upside, but no market access yet.
Ocular disease genome editing
Ocular disease genome editing is a Question Mark for Intellia Therapeutics, Inc.: the SparingVision-linked chance is in a niche, science-led eye market, but it is still precommercial. There are no product sales yet, so market share is 0% today, even if the upside could be high if clinical data and partner execution hold.
- High innovation, no sales
- Zero share, early stage
- Upside depends on data
Engineered cell therapies for oncology and autoimmune disease
Engineered cell therapies for oncology and autoimmune disease sit in high-growth markets, but Intellia Therapeutics, Inc. is still pre-commercial here, with low share and no approved product revenue from these programs. That makes them classic Question Marks: large long-term upside, but they need heavy capital and clean clinical wins to move toward Star.
NTLA’s cell-therapy effort must prove both safety and durable response in late-stage studies; until then, burn stays high and value stays tied to data. If one or more programs reaches approval in a market that can scale across thousands of patients, the share shift can be sharp.
- High-demand oncology and autoimmune markets
- Pre-commercial, so share is still low
- Needs major funding and clinical proof
- Success could re-rate the franchise fast
Intellia’s High-Risk Pipeline Hinges on 2025-2026 Clinical Proof
Intellia Therapeutics, Inc.’s Question Marks are mostly precommercial programs with zero market share today, so value depends on 2025-2026 clinical proof, not sales. NTLA-3001, NTLA-5001, hemophilia, ocular, and cell therapy assets sit in high-need markets, but each still needs durable efficacy and safer editing before share can scale.
| Program | Status | Market signal |
|---|---|---|
| NTLA-3001 | Early | AATD: 1 in 2,000-5,000 |
| NTLA-5001 | Early | AML: ~20,000 U.S. cases |
| Hemophilia/Ocular/Cell | Precommercial | 0% share, high upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.